Advances in the Use of Antiviral Drugs for the Treatment of Mononucleosis

What is Mononucleosis?

The Epstein-Barr virus (EBV) causes mononucleosis which is commonly known as "Kissing Disease" because it is a viral infectious disease. Teenagers and young adults get mononucleosis more often but anyone regardless of age can contract the disease.

Mononucleosis gets its name from the Epstein-Barr virus which causes the disease and belongs to the herpes virus family. The Epstein-Barr virus spreads through saliva transmission which explains why mononucleosis is called "kissing disease". The virus spreads through close contact and sharing of eating utensils or beverages. The Epstein-Barr Virus infects most people during their lifetime yet seldom leads to mononucleosis because it remains inactive in the body.

Table.1 Epstein-Barr virus (EBV) related products at BOC Sciences.

What Virus Causes Mononucleosis?

The Epstein-Barr Virus stands as one of the most widespread human infections globally because its transmission mainly occurs through saliva exchange but it can also move through blood and semen.

The Epstein-Barr virus invades the body and specifically infects epithelial cells in the throat along with B lymphocytes in the immune system. When the virus activates the immune system it results in fever along with sore throat and swollen lymph nodes plus fatigue which represent typical symptoms of mononucleosis.

EBV exposure happens to most people throughout their lives but many do not progress to mononucleosis. Teenagers and young adults show the highest rates of this condition but people from any age group can be affected. The Epstein-Barr virus maintains a dormant state in the body after infection but some people may experience viral reactivation which does not always produce symptoms.

Mononucleosis-like symptoms can also result from infections caused by viruses other than EBV including cytomegalovirus (CMV). EBV stands as the primary cause of mononucleosis among all viruses. Mononucleosis-like symptoms caused by CMV resemble those from EBV but generally present with less severity. Healthcare providers diagnose mononucleosis through clinical symptom evaluation and blood tests that identify antibodies against EBV.

Table.2 Cytomegalovirus (CMV) related products at BOC Sciences.

Epstein-Barr Virus and Mononucleosis

Epstein-Barr virus is a member of the herpesvirus family and is the primary cause of infectious mononucleosis. This virus is one of the most prevalent viruses worldwide, and it is estimated that up to 95% of people will have been infected with EBV by the age of 40. It is transmitted primarily through saliva, though it can also be spread through other bodily fluids such as blood, semen, and organ transplants.

When EBV enters the body, it initially infects epithelial cells in the throat and subsequently targets B lymphocytes, a type of white blood cell. The virus binds to the CD21 receptor on these B cells, which allows it to replicate and establish a lifelong infection. After the initial infection, EBV remains dormant in the body, typically in the B lymphocytes, and can reactivate at any time, often without causing symptoms. In most cases, the immune system is able to control the virus, and it remains in a latent state for the rest of a person's life.

The hallmark symptoms of mononucleosis caused by EBV include fever, sore throat, swollen lymph nodes, and extreme fatigue. The virus triggers an immune response that leads to inflammation, resulting in the characteristic signs of the disease. While some individuals may be asymptomatic or have mild symptoms, others experience more severe illness, especially during the primary infection. The disease is most commonly seen in adolescents and young adults, although it can affect people of all ages.

Diagnosis of EBV-related mononucleosis typically involves blood tests that detect specific antibodies against the virus. A complete blood count (CBC) may show an elevated white blood cell count, including atypical lymphocytes, which further support the diagnosis. A monospot test, which detects heterophile antibodies produced in response to EBV infection, is commonly used as a screening tool.

Although there is no specific antiviral treatment for EBV, the symptoms of mononucleosis can be managed with supportive care. This includes rest, adequate hydration, pain relievers such as acetaminophen or ibuprofen, and gargling with salt water to soothe the sore throat. Corticosteroids may be prescribed in severe cases with significant swelling of the throat or tonsils, but they are not commonly used unless absolutely necessary.

In rare cases, complications such as an enlarged spleen or liver inflammation can occur. People with mononucleosis are advised to avoid physical activities that could lead to injury of the spleen, as it may become enlarged during infection. Most people recover from mono within a few weeks to months, though some experience lingering fatigue for several months after the infection has resolved.

Though EBV is linked to mononucleosis, it is also associated with several other health conditions. Chronic infection with EBV has been linked to certain types of cancer, including Burkitt's lymphoma and nasopharyngeal carcinoma. However, the vast majority of individuals infected with EBV never develop these severe complications. The virus is also linked to autoimmune diseases, including multiple sclerosis and lupus, though the exact mechanisms of this association are still being studied.

In conclusion, Epstein-Barr virus is the primary cause of mononucleosis, and while most cases resolve with supportive care, the virus remains in the body for life. EBV's ability to stay dormant and reactivate over time complicates the understanding of its role in long-term health, and further research is needed to fully grasp its impact on immune function and potential links to other diseases.

Antiviral Drugs for Mononucleosis

Mononucleosis, caused primarily by the Epstein-Barr virus (EBV), does not have a specific antiviral drug for treatment. However, in certain cases, antiviral medications may be used to address complications or severe symptoms. Here are the main chemical antiviral treatments that may be considered in specific circumstances:

Acyclovir

Acyclovir is a commonly used antiviral medication for herpesvirus infections, and although it is not typically used to treat mononucleosis directly, it may be prescribed in cases of complications. Acyclovir works by inhibiting the replication of the virus, specifically targeting viral DNA synthesis. It may be considered if there is a co-infection or if the patient develops severe complications like secondary herpesvirus infections, including oral or genital herpes.

Ganciclovir

Ganciclovir, similar to acyclovir, is another antiviral that targets the viral DNA polymerase to prevent viral replication. It is often used in immunocompromised individuals who are at greater risk of developing severe mononucleosis symptoms. Ganciclovir is not typically prescribed for uncomplicated mononucleosis but may be used if the patient develops complications like cytomegalovirus infection, which is another member of the herpesvirus family that can cause similar symptoms.

Valacyclovir

Valacyclovir is an oral prodrug of acyclovir, meaning it is converted into acyclovir in the body. It can be used in cases of mononucleosis with secondary herpesvirus infections. Like acyclovir, valacyclovir inhibits viral DNA replication. It may be administered if the patient develops an outbreak of herpes simplex virus (HSV), or if secondary infections complicate the mononucleosis diagnosis.

Table.3 Herpes simplex virus (HSV) related products at BOC Sciences.

Corticosteroids (In Severe Cases)

Though not a direct antiviral treatment, corticosteroids like prednisone may be used to reduce inflammation in severe cases of mononucleosis, particularly when complications such as an enlarged spleen or difficulty breathing due to tonsil enlargement occur. Corticosteroids are typically reserved for managing inflammation and swelling rather than directly fighting the Epstein-Barr virus itself.

Antibiotics (For Secondary Bacterial Infections)

While antibiotics are not effective against viral infections like mononucleosis, they may be prescribed if secondary bacterial infections, such as strep throat, develop. Antibiotics do not directly treat EBV but can help resolve complications caused by bacterial infections that may arise during mononucleosis.

Summary

The use of antiviral drugs such as acyclovir and ganciclovir in the treatment of mononucleosis is currently limited. Despite their effectiveness against other herpesviruses, these drugs are not a cure for Epstein-Barr virus, the primary cause of mononucleosis. There is no standard antiviral treatment capable of completely eradicating EBV from the body, making the development of effective antiviral drugs a critical area of research. As it stands, most treatments for mononucleosis are symptomatic, focusing on supportive care such as rest, hydration, and pain management, allowing the body's immune system to fight off the infection.

The development of more targeted antiviral drugs is essential for several reasons. Firstly, antiviral drugs could significantly improve the management of mononucleosis, particularly in immunocompromised individuals who are at greater risk of severe disease and complications. Secondly, as EBV is associated with various long-term health problems, such as certain cancers and autoimmune diseases, the need for drugs that can directly target and control the virus is even more pressing. Effective antiviral therapies could reduce the long-term health burdens associated with chronic EBV infection, preventing more severe outcomes.

In summary, while antiviral drugs may be used in specific cases to manage complications or co-infections, there is no direct antiviral therapy for Epstein-Barr virus itself. This highlights the urgent need for the development of new antiviral treatments, which could offer more effective, targeted, and comprehensive care for those affected by EBV and related conditions. The need for such drugs is not only crucial for improving patient outcomes but also for minimizing the long-term impact of this pervasive virus on global health.

References

• De Paor, Muireann, et al., Antiviral agents for infectious mononucleosis (glandular fever). Cochrane Database of Systematic Reviews 12 (2016).
• Rafailidis, Petros I., et al., Antiviral treatment for severe EBV infections in apparently immunocompetent patients. Journal of clinical virology 49.3 (2010): 151-157.

※ Please kindly note that our services are for research use only.